An observational study in Psoriasis, sponsored by Daewoong Pharmaceutical Co. LTD.. Not yet recruiting. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-09-24.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to evaluate the efficacy and safety of Apremilast tablets in patients with psoriasis over 32 weeks, through a multicenter, single-arm, open-label, phase 4 clinical trial.
In this clinical trial, patients with psoriasis will be informed about study participation and written informed consent will be obtained voluntarily. Eligible participants, based on inclusion and exclusion criteria, will be assigned a registration number. Participants will receive Apremilast for 32 weeks and visit the study site at three time points: Visit 1 (screening and baseline, Week 0), Visit 2 (Week 16 ± 4), and Visit 3 (Week 32 ± 4). At each visit, demographic information, efficacy assessments, and adverse event evaluations will be conducted according to the study schedule.
2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.
This study's planned enrollment of 425 is above the median of 200 across 408 observational studies indexed under Psoriasis.
Browse Psoriasis studies →Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
In the ESTEEM 1 study of moderate-to-severe psoriasis, 33.1% of patients achieved PASI 75 at Week 16 with apremilast, while 28.8% did so in ESTEEM 2. Based on these results, this trial assumed a Week 16 PASI 75 response rate of \~30%. To estimate this with a 95% confidence interval and ±5% margin of error, a sample size of 340 was calculated. If the observed rate is 30%, the Clopper-Pearson method yields a lower bound of 25.2%. The study aims to present the Week 16 PASI 75 response rate with 95% confidence in a single-arm design, ensuring effect size and precision. Considering \~20% dropout, 425 subjects will be enrolled.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients (or their spouse/partner) who do not agree to use medically acceptable and appropriate methods of * during the study period.
* Medically acceptable and appropriate methods of contraception include: hormonal contraception (implants, injectables, oral contraceptives, etc.), intrauterine devices (copper IUD, hormone-releasing intrauterine system), salpingectomy, tubal ligation, hysterectomy, vasectomy, dual barrier methods (male condom and female condom, cervical cap, diaphragm, contraceptive sponge used in combination), or single barrier method combined with spermicide.
(However, patients enrolled in non-interventional studies or who have completed participation in another clinical trial are eligible.)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Apsola Tab. 10mg, Apsola Tab. 20mg, Apsola Tab. 30mg
Proportion of patients who achieved PASI 75
Proportion of patients who achieved PASI 75 at week 16
Time frame: 16 weeks
[Investigator-Assessed Endpoints]Proportion of patients who achieved PASI 75
Proportion of patients who achieved PASI 75 at week 32
Time frame: 32 weeks
[Investigator-Assessed Endpoints]Proportion of patients who achieved PASI 50
Proportion of patients who achieved PASI 50 at weeks 16
Time frame: 16 weeks
[Investigator-Assessed Endpoints]Proportion of patients who achieved PASI 50
Proportion of patients who achieved PASI 50 at weeks 32
Time frame: 32 weeks
[Investigator-Assessed Endpoints]Proportion of patients who achieved PASI 90
Proportion of patients who achieved PASI 90 at weeks 16
Time frame: 16 weeks
[Investigator-Assessed Endpoints]Proportion of patients who achieved PASI 90
Proportion of patients who achieved PASI 90 at weeks 32
Time frame: 32 weeks
[Investigator-Assessed Endpoints]Proportion of patients with an absolute PASI score ≤ 2
Proportion of patients with an absolute PASI score ≤ 2 at weeks 16
Time frame: 16 weeks
[Investigator-Assessed Endpoints]Proportion of patients with an absolute PASI score ≤ 2
Proportion of patients with an absolute PASI score ≤ 2 at weeks 32
Time frame: 32 weeks
[Investigator-Assessed Endpoints]Percentage improvement in mNAPSI (modified Nail Psoriasis Severity Index)
Percentage improvement in mNAPSI (modified Nail Psoriasis Severity Index) from baseline at weeks 16
Time frame: 16 weeks
[Investigator-Assessed Endpoints]Percentage improvement in mNAPSI (modified Nail Psoriasis Severity Index)
Percentage improvement in mNAPSI (modified Nail Psoriasis Severity Index) from baseline at weeks 32
Time frame: 32 weeks
[Investigator-Assessed Endpoints]Proportion of patients who achieved ScPGA (Scalp Physician Global Assessment) score of 0 or 1
Proportion of patients who achieved ScPGA (Scalp Physician Global Assessment) score of 0 or 1 at weeks 16
Time frame: 16 weeks
[Investigator-Assessed Endpoints]Proportion of patients who achieved ScPGA (Scalp Physician Global Assessment) score of 0 or 1
Proportion of patients who achieved ScPGA (Scalp Physician Global Assessment) score of 0 or 1 at weeks 32
Time frame: 32 weeks
[Patient-Reported Endpoints]Change from baseline in DLQI (Dermatology Life Quality Index)
Change from baseline in DLQI (Dermatology Life Quality Index) at weeks 16
Time frame: 16 weeks
[Patient-Reported Endpoints]Change from baseline in DLQI (Dermatology Life Quality Index)
Change from baseline in DLQI (Dermatology Life Quality Index) at weeks 32
Time frame: 32 weeks
[Patient-Reported Endpoints]Change from baseline in Pruritus NRS (Numeric Rating Scale)
Change from baseline in Pruritus NRS (Numeric Rating Scale) at weeks 16
Time frame: 16 weeks
Change from baseline in Pruritus NRS (Numeric Rating Scale)
Change from baseline in Pruritus NRS (Numeric Rating Scale) at weeks 32
Time frame: 32 weeks
[Patient-Reported Endpoints]Change from baseline in PaGA (Patient Global Assessment)
Change from baseline in PaGA (Patient Global Assessment) at weeks 16
Time frame: 16 weeks
[Patient-Reported Endpoints]Change from baseline in PaGA (Patient Global Assessment)
Change from baseline in PaGA (Patient Global Assessment) at weeks 32
Time frame: 32 weeks
[Patient-Reported Endpoints]Shift in distribution of PaGA scores
Shift in distribution of PaGA scores from baseline at weeks 16
Time frame: 16 weeks
[Patient-Reported Endpoints]Shift in distribution of PaGA scores
Shift in distribution of PaGA scores from baseline at weeks 32
Time frame: 32 weeks
[Patient-Reported Endpoints]Proportion of patients who achieved PaGA score of 0 or 1
Proportion of patients who achieved PaGA score of 0 or 1 at weeks 16
Time frame: 16 weeks
[Patient-Reported Endpoints]Proportion of patients who achieved PaGA score of 0 or 1
Proportion of patients who achieved PaGA score of 0 or 1 at weeks 32
Time frame: 32 weeks
No study locations are listed for this record.
Start is estimated for Sep 2025; primary completion for Dec 2026, 15 months later.
Of 81 industry-sponsored observational studies under Psoriasis, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 74. This study's planned 15 months is below that.
Counting every sponsor, half of 174 studies reached it within 37 months; a quarter within 23 and three quarters within 93.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Daewoong Pharmaceutical Co. LTD. →